Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2016-09-20 Share Issue/Capital Cha…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos increases share capital through warrant exercises
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a capital increase resulting from the exercise of warrants by management and directors, leading to the issuance of new shares and an increase in the total share capital. This directly relates to changes in the company's capital structure and financing activities. The key phrases are 'Galapagos verhoogt kapitaal door uitoefening van warrants' (Galapagos increases capital through exercise of warrants) and 'totale kapitaalverhoging van €603.289,80... tot gevolg' (resulting in a total capital increase of €603,289.80). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions director transactions (DIRS), the primary focus and announcement are about the resulting capital change.
2016-09-20 English
Share Capital Increase - 19 September 2016_EN.pdf
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a 'share capital increase through warrant exercises,' detailing the issuance of new ordinary shares and the resulting change in total share capital and voting rights. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). Although it mentions insider transactions (CEO exercising warrants), the primary focus and headline are on the resulting capital change, making SHA the most precise classification over DIRS or CAP.
2016-09-19 English
Share Capital Increase - 19 September 2016_NL.pdf
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a capital increase resulting from the exercise of warrants by management and directors, leading to the issuance of new shares and an increase in the total share capital. This directly relates to changes in the company's capital structure and financing activities. The key phrases are 'Galapagos verhoogt kapitaal door uitoefening van warrants' (Galapagos increases capital through exercise of warrants) and 'totale kapitaalverhoging van €603.289,80... tot gevolg' (resulting in a total capital increase of €603,289.80). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions director transactions (DIRS), the primary focus and announcement are about the resulting capital change.
2016-09-19 Dutch
Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis
Regulatory Filings Classification · 95% confidence The document is titled 'Persbericht' (Press Release) and is dated September 6, 2016. It announces a specific corporate event: the European Commission granting 'orphan drug' status to the drug candidate GLPG1690 for Idiopathic Pulmonary Fibrosis (IPF). This type of announcement, detailing regulatory milestones, clinical trial updates, and strategic corporate news, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a formal press release announcing a significant regulatory development (orphan drug status) and includes forward-looking statements and contact information typical of investor relations communications, it fits best under the 'Earnings Release' category if it contains key financial highlights, or 'Regulatory Filings' if it's purely informational. Given the content focuses heavily on a regulatory/clinical milestone rather than summarizing quarterly financial performance (which would typically be an ER), and it is a formal announcement, 'Regulatory Filings' (RNS) is a strong candidate. However, press releases announcing major clinical/regulatory achievements are often categorized as ERs if they are the primary means of disseminating time-sensitive, material information to the market, even if they aren't strictly quarterly results. Since the definitions provided do not have a specific 'Press Release' or 'Regulatory Milestone Announcement' code, and this is a time-sensitive announcement of material information, it is most closely aligned with an Earnings Release (ER) which often encompasses major news releases, or RNS as a general regulatory announcement. Given the context of a biotech company announcing a regulatory win, ER is often used for such material news. Let's re-evaluate against the definitions. It is not a 10-K, AR, CT, or IP. It is a press release announcing a regulatory event. If it were purely a miscellaneous regulatory filing, RNS would apply. If it were the initial announcement of financial results, ER would apply. Since this is a major, time-sensitive, non-financial result announcement, RNS is the most appropriate fallback for a specific regulatory/corporate announcement not covered elsewhere. However, in many databases, significant press releases are grouped with ERs. Given the strong focus on a regulatory decision and clinical trial progress, RNS (Regulatory Filings) is the safest general classification for a non-standard report announcement.
2016-09-06 English
Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis
Regulatory Filings Classification · 95% confidence The document is a press release dated September 6, 2016, announcing that the European Commission granted 'orphan drug designation' for GLPG1690 for the treatment of idiopathic pulmonary fibrosis (IPF). This is a specific, material event announcement related to drug development and regulatory status, not a comprehensive annual report (10-K), a quarterly report (IR), or a general earnings release (ER). It is a specific corporate update regarding regulatory progress for a drug candidate. While it could potentially fall under 'Regulatory Filings' (RNS), the content is highly specific to a clinical/regulatory milestone, which is best captured by a more general category if a specific one doesn't exist. Since there is no specific 'Drug Development Update' or 'Regulatory Milestone' code, and it is not a formal financial report, it fits best as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the designation implies significant future value, but RNS is the most appropriate fallback for non-standard, material announcements. Given the nature of the announcement (a specific regulatory designation), RNS is the most suitable general category.
2016-09-06 English
FINCH filgotinib Phase 3 program initiated in rheumatoid arthritis
Regulatory Filings Classification · 95% confidence The document is titled 'Persbericht' (Press Release) and announces the start of the FINCH Phase 3 program for the drug filgotinib in rheumatoid arthritis. It details the structure of three clinical studies (FINCH 1, 2, and 3), provides quotes from management, and includes contact information and forward-looking statements. This format is characteristic of an initial announcement of significant corporate or clinical development news, rather than a comprehensive periodic report (like 10-K or IR) or a transcript. Since it is a press release announcing clinical trial progress and is not a general regulatory filing fallback (RNS) or a specific financial report, the most appropriate classification is 'Earnings Release' (ER) if it were financial results, but since it is clinical/operational news, it fits best under the general 'Regulatory Filings' (RNS) category as a broad announcement, or potentially 'LTR' if it were a legal update, but here it is a development update. Given the options, and recognizing that press releases announcing operational milestones often fall into the general regulatory/announcement bucket when a more specific one isn't available, RNS is the best fit for a general corporate announcement that isn't a financial report or management change. However, since it is a detailed announcement of a major clinical program start, it is a significant corporate event announcement. If we strictly follow the definitions, it is not an ER (which is for financial results). It is not MANG, DIRS, DIV, etc. It is a general corporate update. RNS is the fallback for miscellaneous filings. Given the context of a press release announcing clinical trial initiation, RNS is the most suitable general announcement category.
2016-08-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.